EKSO Ekso Bionics Holdings Inc

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Ekso Bionics Holdings, Inc.

NEW YORK--(BUSINESS WIRE)--

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of purchasers of the securities of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) resulting from allegations that Ekso Bionics may have issued materially misleading business information to the investing public.

On December 14, 2017, Ekso Bionics stated that “the Company’s internal control over financial reporting as of December 31, 2016 should no longer be relied upon and that a material weakness in the Company’s internal control over financial reporting existed as of such date.” On this news, Ekso’s share price fell $0.15, or 6.17%, to close at $2.28 on December 15, 2017. Then, on December 27, 2017, during aftermarket hours, Ekso Bionics filed an amended annual report for 2016 and amended quarterly reports for the first three quarters of 2017. On this news, shares of Ekso Bionics fell sharply during intraday trading on December 28, 2017.

Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Ekso Bionics investors. If you purchased shares of Ekso Bionics, please visit the firm’s website at http://www.rosenlegal.com/cases-1262.html for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

EN
28/12/2017

Underlying

EKSOEkso Bionics Holdings Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ekso Bionics Holdings Inc

 PRESS RELEASE
Free
EKSO Ekso Bionics Ho...

Ekso Bionics Prices $5.852 million Private Placement

Ekso Bionics Prices $5.852 million Private Placement SAN RAFAEL, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that on January 20, 2026 it entered into securities purchase agreements with certain institutional and accredited investors for the purchase and sale of an aggregate of 5,852 shares of the Company’s Series B Preferred Stock (the “Preferred Stock”) and warrants (the “Warrants”) to purchase up to an aggregate of 355,960 shares of common stock o...

January 21, 2026 1 EN
 PRESS RELEASE
Free
EKSO Ekso Bionics Ho...

Ekso Bionics Inks Agreement to Become the Exclusive U.S. Distributor o...

Ekso Bionics Inks Agreement to Become the Exclusive U.S. Distributor of MediTouch’s Groundbreaking BalanceTutor™ Rehabilitation System SAN RAFAEL, Calif. and TNUVOT, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has entered into an agreement with Israel-based MediTouch Inc. (“MediTouch”) to become the exclusive authorized sales agent and distributor of MediTouch’s rehabilitation system in the United States. The Bal...

December 4, 2025 1 EN
 PRESS RELEASE
Free
EKSO Ekso Bionics Ho...

Ekso Bionics Announces $3.7 Million Registered Direct Offering of Comm...

Ekso Bionics Announces $3.7 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules SAN RAFAEL, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that on October 28, 2025, it entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 769,490 shares of the Company’s common stock at a purchase price of $4.81 per share of common stock in a registered direct offering...

October 29, 2025 1 EN
 PRESS RELEASE
Free
EKSO Ekso Bionics Ho...

Ekso Bionics Reports Third Quarter 2025 Financial Results

Ekso Bionics Reports Third Quarter 2025 Financial Results SAN RAFAEL, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and nine months ended September 30, 2025. Third Quarter 2025 Highlights and Accomplishments Revenue grew 2% year-over-year and rebounded 105% sequentially quarter-over-quarter to $4.2 millionGross margin increased 680 basis points year-over-year and 2,050 basis points sequential...

October 28, 2025 1 EN
 PRESS RELEASE
Free
EKSO Ekso Bionics Ho...

Ekso Bionics Reports Second Quarter 2025 Financial Results

Ekso Bionics Reports Second Quarter 2025 Financial Results SAN RAFAEL, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and six months ended June 30, 2025. Recent Highlights and Accomplishments Named Bionic Prosthetics & Orthotics Group (“Bionic P&O”) as its first Ekso Indego Personal device distributor within the orthotics and prosthetics industryAccepted into the NVIDIA Connect program, suppor...

July 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch